ArticleScientific reports2025
Efficacy of the silicon based agent for age related decline in vestibular function.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vestibular functional assessment using the caloric test in mice with arsanilic acid-induced vestibular dysfunction.Biochemistry and biophysics reports · 2026Article
- Efficacy of silicon-based agent against aging-related frailty.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Age-related vertigo and balance disorders can lead to falls, fractures, and prolonged confinement to bed. Loss of mobility and/or social interaction may cause cognitive decline and lower quality of life, resulting in significant social and economic burdens. Aging societies urgently need treatments for vestibular decline, as no cures exist, and current therapies only provide symptomatic relief. Oxidative stress contributes to age-related cochlear balance system damage, making antioxidants a potential treatment. Silicon-based agent (Si-agent) is an excellent antioxidant. When reacting with water, this agent produces hydrogen continuously, offering sustained antioxidant effects. Oral Si-agent has alleviated oxidative stress-related diseases in mouse models, such as ulcerative colitis and Parkinson's disease. This study evaluated Si-agent for age-related vestibular decline in mice. In balance beam tests, Si-agents-treated group showed less balance decline with age compared to untreated mice. However, vestibulo-ocular reflex (VOR) tests measuring semicircular canal and otolith organ function showed no significant differences. In linear VOR, no significant differences were observed at any frequency; however, a significant difference was found in the average slope of linear decline between 0.7 and 0.9 G. Structural damage to the inner ear's semicircular canals and otolith organs was also reduced in Si-agents-treated group. These findings suggest that Si- agent may help treat age-related in balance and motor decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.